{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T06:04:53Z","timestamp":1785045893286,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Health Popul Nutr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in reducing blood lipid levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with hyperlipidaemia admitted to the cardiac centre between January 2019 and December 2020 were included in the study. A total of 1063 patients with hyperlipidaemia took either Shanhuang Jiangzhi tablets (<jats:italic>n<\/jats:italic>\u2009=\u2009372) or atorvastatin (<jats:italic>n<\/jats:italic>\u2009=\u2009691) and met the inclusion and exclusion criteria. Clinical data, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, were retrospectively evaluated after propensity score matching (PSM) analysis. The adverse events were also recorded during the therapy process.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following PSM analysis, both groups were well matched across all parameters. Compared with the baseline, Shanhuang Jiangzhi tablets had greater effects on TC, TG and LDL-C, and the difference was statistically significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, the results showed that Shanhuang Jiangzhi tablets are similar to atorvastatin in reducing TC and LDL-C, and all <jats:italic>p<\/jats:italic>-values were\u2009&gt;\u20090.05. However, the decrease of TG was greater in the Shanhuang Jiangzhi group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Clinical adverse reactions of Shanhuang Jiangzhi tablets are rare and have no statistical significance compared with atorvastatin (<jats:italic>p<\/jats:italic>\u2009=\u20090.682).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41043-023-00482-3","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:03:28Z","timestamp":1702569808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia"],"prefix":"10.1186","volume":"42","author":[{"given":"GuoTong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiuWen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"9 Suppl","key":"482_CR1","first-page":"S139","volume":"23","author":"S Karr","year":"2017","unstructured":"Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139\u201348.","journal-title":"Am J Manag Care"},{"issue":"2","key":"482_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/10799891003630606","volume":"30","author":"L Ivan","year":"2010","unstructured":"Ivan L, Antohe F. Hyperlipidemia induces endothelial-derived foam cells in culture. J Recept Signal Transduct Res. 2010;30(2):106\u201314. https:\/\/doi.org\/10.3109\/10799891003630606.","journal-title":"J Recept Signal Transduct Res"},{"issue":"2","key":"482_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clinthera.2011.02.011","volume":"33","author":"HS Friedman","year":"2011","unstructured":"Friedman HS, Rajagopalan S, Barnes JP, Roseman H. Combination therapy with ezetimibe\/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Clin Ther. 2011;33(2):212\u201324. https:\/\/doi.org\/10.1016\/j.clinthera.2011.02.011.","journal-title":"Clin Ther"},{"issue":"2","key":"482_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1142\/S0192415X19500150","volume":"47","author":"TJ Wang","year":"2019","unstructured":"Wang TJ, Lien AS, Chen JL, Lin CH, Yang YS, Yang SH. A randomized clinical efficacy trial of red yeast rice (Monascus pilosus) against hyperlipidemia. Am J Chin Med. 2019;47(2):323\u201335. https:\/\/doi.org\/10.1142\/S0192415X19500150.","journal-title":"Am J Chin Med"},{"key":"482_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008305","author":"ZL Liu","year":"2011","unstructured":"Liu ZL, Liu JP, Zhang AL, Wu Q, Ruan Y, Lewith G, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD008305.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"482_CR6","first-page":"409","volume":"25","author":"H Wang","year":"2018","unstructured":"Wang H, Wang H. Effects of combining Sanhuang lipid lowering formula and statins on carotid atherosclerotic plaques. Chinese J Tradit Med Sci Technol. 2018;25(3):409\u201311.","journal-title":"Chinese J Tradit Med Sci Technol"},{"issue":"3","key":"482_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3969\/j.issn.1000-6834.2007.03.024","volume":"23","author":"Z Xu","year":"2007","unstructured":"Xu Z, Lu Z, Chen Y, Deng X, Mao Y, Huo X. The effect of rhubarb ethanol-extract on hyperlipidemia and liver fatty in rabbits. Chinese J Appl Physiol. 2007;23(3):375\u201380. https:\/\/doi.org\/10.3969\/j.issn.1000-6834.2007.03.024.","journal-title":"Chinese J Appl Physiol"},{"issue":"4","key":"482_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.4268\/cjcmm20150404","volume":"40","author":"Y Yuan","year":"2015","unstructured":"Yuan Y, Wu Q, Shi J, Chen X. Advance in studies on hepatoprotective effect of Salvia miltiorrhiza and its main components. China J Chin Materia Med. 2015;40(4):588\u201393. https:\/\/doi.org\/10.4268\/cjcmm20150404.","journal-title":"China J Chin Materia Med"},{"issue":"1","key":"482_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1423-0127-18-30","volume":"18","author":"JH Ho","year":"2011","unstructured":"Ho JH, Hong CY. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci. 2011;18(1):30. https:\/\/doi.org\/10.1186\/1423-0127-18-30.","journal-title":"J Biomed Sci"},{"issue":"3","key":"482_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1005-5304.2005.03.030","volume":"12","author":"BF Yu","year":"2005","unstructured":"Yu BF, Qian CL. Shanhuang Jiangzhi tablets for the treatment of 150 cases of fatty liver. Chinese J Tradit Chinese Med Inf. 2005;12(3):1. https:\/\/doi.org\/10.3969\/j.issn.1005-5304.2005.03.030.","journal-title":"Chinese J Tradit Chinese Med Inf"},{"issue":"8","key":"482_CR11","first-page":"3","volume":"25","author":"LJ Chen","year":"2019","unstructured":"Chen LJ, Yu BF, Liu M, Wang X, Hansi GL, Bi LG. Study on the determination of Puerarin content in Shanhuang Jiangzhi tablets. Chinese J Ethnic Med. 2019;25(8):3.","journal-title":"Chinese J Ethnic Med"},{"issue":"1","key":"482_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195\u2013211. https:\/\/doi.org\/10.1016\/j.pop.2012.11.003.","journal-title":"Prim Care"},{"key":"482_CR13","unstructured":"HHS, U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https:\/\/www.meddra.org\/."},{"issue":"3","key":"482_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2146\/060104","volume":"64","author":"MF Bullano","year":"2007","unstructured":"Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007;64(3):276\u201384. https:\/\/doi.org\/10.2146\/060104.","journal-title":"Am J Health Syst Pharm"},{"issue":"25","key":"482_CR15","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25):2889\u2013934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"482_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bj\u00f6rnsson","year":"2012","unstructured":"Bj\u00f6rnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.023.","journal-title":"J Hepatol"},{"issue":"1\u20132","key":"482_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0021-9150(96)06052-2","volume":"130","author":"S Bertolini","year":"1997","unstructured":"Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130(1\u20132):191\u20137. https:\/\/doi.org\/10.1016\/s0021-9150(96)06052-2.","journal-title":"Atherosclerosis"},{"issue":"9","key":"482_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","volume":"23","author":"D Rosenbaum","year":"2013","unstructured":"Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23(9):871\u20135. https:\/\/doi.org\/10.1016\/j.numecd.2012.04.012.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"482_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1378\/chest.08-0943","volume":"134","author":"AB Fern\u00e1ndez","year":"2008","unstructured":"Fern\u00e1ndez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008;134(4):824\u201330. https:\/\/doi.org\/10.1378\/chest.08-0943.","journal-title":"Chest"},{"issue":"6","key":"482_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","volume":"14","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance\u2014an attempt at a unified definition. Position paper from an international lipid expert panel. Expert Opin Drug Saf. 2015;14(6):935\u201355. https:\/\/doi.org\/10.1517\/14740338.2015.1039980.","journal-title":"Expert Opin Drug Saf"},{"key":"482_CR21","doi-asserted-by":"publisher","first-page":"6633402","DOI":"10.1155\/2021\/6633402","volume":"2021","author":"G Yuan","year":"2021","unstructured":"Yuan G, Shi S, Jia Q, Shi J, Shi S, Zhang X, et al. Use of network pharmacology to explore the mechanism of Gegen (Puerariae lobatae Radix) in the treatment of type 2 diabetes mellitus associated with hyperlipidemia. Evid Based Complement Alternat Med. 2021;2021:6633402. https:\/\/doi.org\/10.1155\/2021\/6633402.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"12","key":"482_CR22","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1016\/j.fct.2011.09.007","volume":"49","author":"CM Liu","year":"2011","unstructured":"Liu CM, Ma JQ, Sun YZ. Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. Food Chem Toxicol. 2011;49(12):3119\u201327. https:\/\/doi.org\/10.1016\/j.fct.2011.09.007.","journal-title":"Food Chem Toxicol"},{"issue":"11","key":"482_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078731","volume":"8","author":"M Wang","year":"2013","unstructured":"Wang M, Wang F, Wang Y, Ma X, Zhao M, Zhao C. Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats. PLoS ONE. 2013;8(11): e78731. https:\/\/doi.org\/10.1371\/journal.pone.0078731.","journal-title":"PLoS ONE"},{"issue":"11","key":"482_CR24","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1248\/bpb.b17-00218","volume":"40","author":"Z Xian","year":"2017","unstructured":"Xian Z, Liu Y, Xu W, Duan F, Guo Z, Xiao H. The anti-hyperlipidemia effects of raw polygonum multiflorum extract in vivo. Biol Pharm Bull. 2017;40(11):1839\u201345. https:\/\/doi.org\/10.1248\/bpb.b17-00218.","journal-title":"Biol Pharm Bull"},{"key":"482_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111846","volume":"141","author":"G Sun","year":"2021","unstructured":"Sun G, Li X, Wei J, Zhang T, Li B, Chen M, Wang Y, Chen K, Li Y. Pharmacodynamic substances in Salvia miltiorrhiza for prevention and treatment of hyperlipidemia and coronary heart disease based on lipidomics technology and network pharmacology analysis. Biomed Pharmacother. 2021;141: 111846. https:\/\/doi.org\/10.1016\/j.biopha.2021.111846.","journal-title":"Biomed Pharmacother"},{"key":"482_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115101","volume":"290","author":"Z Xie","year":"2022","unstructured":"Xie Z, Li EW, Gao G, Du Y, Wang M, Wang H, et al. Zexie Tang targeting FKBP38\/mTOR\/SREBPs pathway improves hyperlipidemia. J Ethnopharmacol. 2022;290: 115101. https:\/\/doi.org\/10.1016\/j.jep.2022.115101.","journal-title":"J Ethnopharmacol"},{"issue":"21","key":"482_CR27","doi-asserted-by":"publisher","first-page":"10484","DOI":"10.1039\/d1fo01849c","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Wang R, Li L, Yan Y, Jia S, Jiang H, et al. Quantitative proteomics of plasma and liver reveals the mechanism of turmeric in preventing hyperlipidemia in mice. Food Funct. 2021;12(21):10484\u201399. https:\/\/doi.org\/10.1039\/d1fo01849c.","journal-title":"Food Funct"},{"issue":"4","key":"482_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/1750-3841.14491","volume":"84","author":"C Hu","year":"2019","unstructured":"Hu C, Zhang Y, Liu G, Liu Y, Wang J, Sun B. Untargeted metabolite profiling of adipose tissue in hyperlipidemia rats exposed to hawthorn ethanol extracts. J Food Sci. 2019;84(4):717\u201325. https:\/\/doi.org\/10.1111\/1750-3841.14491.","journal-title":"J Food Sci"},{"issue":"5","key":"482_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/jssc.202000911","volume":"44","author":"L Zeng","year":"2021","unstructured":"Zeng L, Luo L, Xue Q, He Q, Chen X, Meng J, Wang S, Liang S. LC-MS based plasma metabolomics study of the intervention effect of different polar parts of Hawthorn on hyperlipidemia rats. J Sep Sci. 2021;44(5):963\u201372. https:\/\/doi.org\/10.1002\/jssc.202000911.","journal-title":"J Sep Sci"},{"key":"482_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.biopha.2017.08.075","volume":"95","author":"R Vijayakumar","year":"2017","unstructured":"Vijayakumar R, Nachiappan V. Cassia auriculata flower extract attenuates hyperlipidemia in male Wistar rats by regulating the hepatic cholesterol metabolism. Biomed Pharmacother. 2017;95:394\u2013401. https:\/\/doi.org\/10.1016\/j.biopha.2017.08.075.","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Health, Population and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-023-00482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41043-023-00482-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-023-00482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:07:36Z","timestamp":1702570056000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhpn.biomedcentral.com\/articles\/10.1186\/s41043-023-00482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1186\/s41043-023-00482-3","relation":{},"ISSN":["2072-1315"],"issn-type":[{"value":"2072-1315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Hulunbuir Zhong Meng Hospital. The latter waived written informed consent because of the retrospective nature of our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"143"}}